RxDoctor Payments Data

Mary Barkley

Family · Rockford, ILNPI 1669053765

Payments from drug & device makers

$961in general payments, 2019–2025

Across 22 payments — averaging $43.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$298
  • Teva Pharmaceuticals USA, Inc.$193
  • Alkermes, Inc.$121
  • Amgen$108
  • Sumitomo Pharma America, Inc.$104
  • Insulet Corporation$45
  • plus $92 from 3 others

What the payments were for

  • Food & beverage$89093%
  • Education$717%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$961 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$127,444
Medicare patients
138
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$33,822
GemtesaVibegron78$18,794
VraylarCariprazine Hcl16$11,437
JanuviaSitagliptin Phosphate38$11,010
JardianceEmpagliflozin21$7,408
FarxigaDapagliflozin Propanediol18$5,847
MultaqDronedarone Hcl12$4,556
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen162$4,407
Duloxetine Hcl98$3,680
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$3,624
TradjentaLinagliptin13$3,541
Potassium Chloride77$2,870
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$2,682
Atorvastatin Calcium141$2,375
Allopurinol47$2,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$104$18,79478 claims
AbbVieVraylar$35$11,43716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,941 family providers in Illinois.

Other family in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →